Jagsonpal Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/90aq8qpouxg3l2qy8c88p7f5.pdf

Key Takeaways


Quarterly Performance & the Internal Reset

Manish Gupta: "The last quarter saw strengthening of our leadership team... Coming to the performance during the quarter, it was at best flattish. We acknowledge that this outcome has been below our own expectations as well as relative to the broader Indian pharmaceutical market."

Leadership & Strategic Direction

Amrut Medhekar: "Yes, of course. So, we'll bet on the winning horses."

Yash Pharma Acquisition


Growth Outlook & Q4 Acceleration

Amrut Medhekar: "Our idea, Sajal, at least what I am aiming in the short term is 50% more than the industry growth."

Capital Allocation

Manish Gupta: "M&A is a very strong intent at our end, but a disciplined M&A which is accretive for our shareholders and not dilutive. So that's very, very important for us. Market has not been supportive in terms of cost or price of acquisition."

Guidance & Commitments

CommitmentSpecificsTimeline
Growth accelerationDouble-digit growth, upward of 10%Q4 FY26
Short-term growth vs industry50% more than industry growthShort term (undated)
Long-term organic growth12% to 14% organic growthThree to four years, assuming no macro or external changes
Product launches in high-growth territoryBetter yield per patientEnd of H1 in the coming financial year
Capital deploymentM&A (accretive) or return to shareholders; disciplined approachOngoing, subject to reasonable asset prices

Key Metrics

MetricQ3 FY26
Revenue₹73 cr, flattish
Revenue growth-1%, impacted by internal recalibration and post-GST adjustment
EBITDA₹16.7 cr
EBITDA margin22.7%
PAT₹12.5 cr, +10% YoY
PAT margin17.1%, improved 180 bps YoY
9M FY26 revenue₹223 cr, +6% YoY
9M FY26 EBITDA₹50.3 cr, +5% YoY, margin at 22.6%
9M FY26 PAT₹35.9 cr, +12.5% YoY, margin at 16.1%
Free cash balance₹176 cr, increased by ₹15.2 cr in the quarter
Stock cash generationOver ₹15 cr during the quarter
IPM growth~8%, largely driven by price growth of 5% to 5.5%, volume growth muted
RPM growth3% to 3.5%, slower than IPM
One-time labour code impact₹2.1 cr, exceptional item
Revenue impact from SKU rationalization~1.5% to 2% of top line value